首页> 外文期刊>Critical care medicine >Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: A randomized controlled trial
【24h】

Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: A randomized controlled trial

机译:米力农治疗儿童肠道病毒71型肺水肿和/或神经源性休克:一项随机对照试验

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE:: Enterovirus 71-induced brainstem encephalitis with pulmonary edema and/or neurogenic shock (stage 3B) is associated with rapid mortality in children. In a small pilot study, we found that milrinone reduced early mortality compared with historical controls. This prospective, randomized control trial was designed to provide more definitive evidence of the ability of milrinone to reduce the 1-week mortality of stage 3B enterovirus 71 infections. DESIGN:: Prospective, unicenter, open-label, randomized, controlled study. SETTING:: Inpatient ward of a large tertiary teaching hospital in Ho Chi Minh City, Vietnam. PATIENTS:: Children (≤18 yr old) admitted with proven enterovirus 71-induced pulmonary edema and/or neurogenic shock. INTERVENTIONS:: Patients were randomly assigned to receive intravenous milrinone (0.5 μg/kg/min) (n = 22) or conventional management (n = 19). Both groups received dopamine or dobutamine and intravenous immunoglobulin. MEASUREMENTS AND MAIN RESULTS:: The primary endpoint was 1-week mortality. The secondary endpoints included length of ventilator dependence and hospital stay and adverse events. The median age was 2 years with a predominance of boys in both groups. The 1-week mortality was significantly lower, 18.2% (4/22) in the milrinone compared with 57.9% (11/19) in the conventional management group (relative risk = 0.314 [95% CI, 0.12-0.83], p = 0.01). The median duration of ventilator-free days was longer in the milrinone treatment group (p = 0.01). There was no apparent neurologic sequela in the survivors in either group, and no drug-related adverse events were documented. CONCLUSIONS:: Milrinone significantly reduced the 1-week mortality of enterovirus 71-induced pulmonary edema and/or neurogenic shock without adverse effects. Further studies are needed to determine whether milrinone might be useful to prevent progression of earlier stages of brainstem encephalitis.
机译:目的:肠病毒71诱导的脑干脑炎伴肺水肿和/或神经源性休克(3B期)与儿童快速死亡相关。在一项小型先导研究中,我们发现米力农与历史对照组相比可降低早期死亡率。这项前瞻性,随机对照试验旨在为米力农降低3B期肠病毒71期感染1周死亡率的能力提供更多确定的证据。设计::前瞻性,单中心,开放标签,随机对照研究。地点:越南胡志明市一家大型三级教学医院的住院病房。患者:≤18岁的儿童经确诊肠病毒71诱导的肺水肿和/或神经源性休克。干预措施:患者被随机分配接受静脉注射米力农(0.5μg/ kg / min)(n = 22)或常规治疗(n = 19)。两组均接受多巴胺或多巴酚丁胺和静脉注射免疫球蛋白。测量和主要结果:主要终点为1周死亡率。次要终点包括呼吸机依赖时间,住院时间和不良事件。两组的平均年龄为2岁,其中以男孩为主。米力农的1周死亡率显着降低,为18.2%(4/22),而常规管理组为57.9%(11/19)(相对风险= 0.314 [95%CI,0.12-0.83],p = 0.01)。米力农治疗组无呼吸机天数的中位数持续时间更长(p = 0.01)。两组中的幸存者均没有明显的神经后遗症,也未记录到与药物相关的不良事件。结论:米力农显着降低了肠道病毒71诱导的肺水肿和/或神经性休克的1周死亡率,而没有不良影响。需要进一步的研究以确定米力农是否对预防脑干脑炎早期发展有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号